Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis

Implications for passive immunotherapy

David L. Goldman, Arturo Casadevall, L. S. Zuckier

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Several investigators have developed monoclonal antibodies against the capsular polysaccharide of Cryptococcus neoformans which have potential therapeutic applications. Using a rat model of C. neoformans meningitis, we studied the biodistribution and pharmacokinetics of a murine anticryptococcal capsular monoclonal antibody (mAb 2H1) after intravenous and intracisternal administration. After intravenous administration of 125I-labelled 2H1 to infected rats, there was no detectable localization of 125I in the brain or cerebrospinal fluid by either gamma-camera imaging of the whole animal or organ scintillation counting. In contrast, direct intracisternal instillation of 2H1 to infected rats resulted in persistent intracranial activity. In addition, the whole body half-life of intravenously administered radio labelled mAb 2H1 was significantly reduced in infected rats compared with uninfected rats. Our observations suggest that if high central nervous system (CNS) levels of mAb are needed to achieve a therapeutic effect in human C. neoformans meningoencephalitis, direct administration of mAb into the cerebrospinal fluid or modification of the mAb to increase penetration into the CNS may be required. Furthermore, higher or more frequent dosing of mAb may be required to maintain therapeutic levels in the presence of infection. This study demonstrates the usefulness of the rat as an experimental system for studying issues related to cryptococcosis.

Original languageEnglish (US)
Pages (from-to)271-278
Number of pages8
JournalMedical Mycology
Volume35
Issue number4
DOIs
StatePublished - 1997

Fingerprint

Cryptococcal Meningitis
Cryptococcus neoformans
Passive Immunization
meningitis
immunotherapy
pharmacokinetics
Polysaccharides
monoclonal antibodies
polysaccharides
Pharmacokinetics
animal models
Monoclonal Antibodies
antigens
Antigens
rats
cerebrospinal fluid
therapeutics
central nervous system
Intravenous Administration
Cerebrospinal Fluid

Keywords

  • Cryptococcus neoformans
  • distribution
  • kinetics
  • monoclonal antibody

ASJC Scopus subject areas

  • veterinary(all)
  • Infectious Diseases

Cite this

@article{24c252e19d354d6c8c3f1d03b739eca9,
title = "Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis: Implications for passive immunotherapy",
abstract = "Several investigators have developed monoclonal antibodies against the capsular polysaccharide of Cryptococcus neoformans which have potential therapeutic applications. Using a rat model of C. neoformans meningitis, we studied the biodistribution and pharmacokinetics of a murine anticryptococcal capsular monoclonal antibody (mAb 2H1) after intravenous and intracisternal administration. After intravenous administration of 125I-labelled 2H1 to infected rats, there was no detectable localization of 125I in the brain or cerebrospinal fluid by either gamma-camera imaging of the whole animal or organ scintillation counting. In contrast, direct intracisternal instillation of 2H1 to infected rats resulted in persistent intracranial activity. In addition, the whole body half-life of intravenously administered radio labelled mAb 2H1 was significantly reduced in infected rats compared with uninfected rats. Our observations suggest that if high central nervous system (CNS) levels of mAb are needed to achieve a therapeutic effect in human C. neoformans meningoencephalitis, direct administration of mAb into the cerebrospinal fluid or modification of the mAb to increase penetration into the CNS may be required. Furthermore, higher or more frequent dosing of mAb may be required to maintain therapeutic levels in the presence of infection. This study demonstrates the usefulness of the rat as an experimental system for studying issues related to cryptococcosis.",
keywords = "Cryptococcus neoformans, distribution, kinetics, monoclonal antibody",
author = "Goldman, {David L.} and Arturo Casadevall and Zuckier, {L. S.}",
year = "1997",
doi = "10.1080/02681219780001261",
language = "English (US)",
volume = "35",
pages = "271--278",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis

T2 - Implications for passive immunotherapy

AU - Goldman, David L.

AU - Casadevall, Arturo

AU - Zuckier, L. S.

PY - 1997

Y1 - 1997

N2 - Several investigators have developed monoclonal antibodies against the capsular polysaccharide of Cryptococcus neoformans which have potential therapeutic applications. Using a rat model of C. neoformans meningitis, we studied the biodistribution and pharmacokinetics of a murine anticryptococcal capsular monoclonal antibody (mAb 2H1) after intravenous and intracisternal administration. After intravenous administration of 125I-labelled 2H1 to infected rats, there was no detectable localization of 125I in the brain or cerebrospinal fluid by either gamma-camera imaging of the whole animal or organ scintillation counting. In contrast, direct intracisternal instillation of 2H1 to infected rats resulted in persistent intracranial activity. In addition, the whole body half-life of intravenously administered radio labelled mAb 2H1 was significantly reduced in infected rats compared with uninfected rats. Our observations suggest that if high central nervous system (CNS) levels of mAb are needed to achieve a therapeutic effect in human C. neoformans meningoencephalitis, direct administration of mAb into the cerebrospinal fluid or modification of the mAb to increase penetration into the CNS may be required. Furthermore, higher or more frequent dosing of mAb may be required to maintain therapeutic levels in the presence of infection. This study demonstrates the usefulness of the rat as an experimental system for studying issues related to cryptococcosis.

AB - Several investigators have developed monoclonal antibodies against the capsular polysaccharide of Cryptococcus neoformans which have potential therapeutic applications. Using a rat model of C. neoformans meningitis, we studied the biodistribution and pharmacokinetics of a murine anticryptococcal capsular monoclonal antibody (mAb 2H1) after intravenous and intracisternal administration. After intravenous administration of 125I-labelled 2H1 to infected rats, there was no detectable localization of 125I in the brain or cerebrospinal fluid by either gamma-camera imaging of the whole animal or organ scintillation counting. In contrast, direct intracisternal instillation of 2H1 to infected rats resulted in persistent intracranial activity. In addition, the whole body half-life of intravenously administered radio labelled mAb 2H1 was significantly reduced in infected rats compared with uninfected rats. Our observations suggest that if high central nervous system (CNS) levels of mAb are needed to achieve a therapeutic effect in human C. neoformans meningoencephalitis, direct administration of mAb into the cerebrospinal fluid or modification of the mAb to increase penetration into the CNS may be required. Furthermore, higher or more frequent dosing of mAb may be required to maintain therapeutic levels in the presence of infection. This study demonstrates the usefulness of the rat as an experimental system for studying issues related to cryptococcosis.

KW - Cryptococcus neoformans

KW - distribution

KW - kinetics

KW - monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=80051487937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051487937&partnerID=8YFLogxK

U2 - 10.1080/02681219780001261

DO - 10.1080/02681219780001261

M3 - Article

VL - 35

SP - 271

EP - 278

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 4

ER -